Phase 2b Study of JNJ-88545223 to Treat Active Psoriatic Arthritis in Adults Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial

What this Trial Is About

Researchers are studying the drug JNJ-88545223 to see how well it works compared with a placebo in adults who have active psoriatic arthritis PsA. This study aims to determine if JNJ-88545223 can reduce the signs and symptoms of PsA and improve the health of joints and skin. The trial is a randomized, double-blind phase 2b study designed to evaluate different doses of the drug. Participants will be randomly assigned to receive one of four treatments from Week 0 to Week 16 placebo, or one of three doses of JNJ-88545223. Each group will receive their assigned treatment under blinded conditions to compare the effects. The study focuses on evaluating the efficacy and safety of these doses over the 16-week treatment period. During the study, participants will undergo regular assessments to measure treatment effects, including the American College of Rheumatology ACR 50 response at Week 16 as the primary outcome. Additional evaluations include skin severity indexes PASI responses, physical function questionnaires, and quality of life surveys. Safety and symptoms will be monitored throughout the trial, which lasts approximately 16 weeks for each participant.

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis